+

WO2009066967A3 - Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer - Google Patents

Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer Download PDF

Info

Publication number
WO2009066967A3
WO2009066967A3 PCT/KR2008/006926 KR2008006926W WO2009066967A3 WO 2009066967 A3 WO2009066967 A3 WO 2009066967A3 KR 2008006926 W KR2008006926 W KR 2008006926W WO 2009066967 A3 WO2009066967 A3 WO 2009066967A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
evaluating
compositions
methods
microrna
Prior art date
Application number
PCT/KR2008/006926
Other languages
English (en)
Other versions
WO2009066967A2 (fr
Inventor
Hee Kyung Park
Su Young Oh
Original Assignee
Panagene Inc
Hee Kyung Park
Su Young Oh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagene Inc, Hee Kyung Park, Su Young Oh filed Critical Panagene Inc
Priority to JP2010534896A priority Critical patent/JP2011504110A/ja
Priority to EP08851799A priority patent/EP2215228A4/fr
Priority to US12/741,413 priority patent/US20100240058A1/en
Publication of WO2009066967A2 publication Critical patent/WO2009066967A2/fr
Publication of WO2009066967A3 publication Critical patent/WO2009066967A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des ANP antisens à microARN capables d'inhiber l'activité ou la fonction d'un microARN, une composition pour inhiber l'activité ou la fonction d'un microARN les contenant, un procédé pour inhiber l'activité ou la fonction d'un microARN les utilisant, et un procédé pour évaluer leur efficacité.
PCT/KR2008/006926 2007-11-23 2008-11-24 Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer WO2009066967A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2010534896A JP2011504110A (ja) 2007-11-23 2008-11-24 マイクロｒｎａアンチセンスｐｎａ、これを含む組成物、及びその使用及び評価方法
EP08851799A EP2215228A4 (fr) 2007-11-23 2008-11-24 Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer
US12/741,413 US20100240058A1 (en) 2007-11-23 2008-11-24 MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2007-0120459 2007-11-23
KR20070120459 2007-11-23
KR10-2008-0116856 2008-11-24
KR1020080116856A KR101026502B1 (ko) 2007-11-23 2008-11-24 마이크로ｒｎａ 안티센스 ｐｎａ, 그를 포함하는 조성물, 및 그의 사용 및 평가 방법

Publications (2)

Publication Number Publication Date
WO2009066967A2 WO2009066967A2 (fr) 2009-05-28
WO2009066967A3 true WO2009066967A3 (fr) 2009-08-20

Family

ID=40668011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/006926 WO2009066967A2 (fr) 2007-11-23 2008-11-24 Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer

Country Status (5)

Country Link
US (1) US20100240058A1 (fr)
EP (2) EP2520649A3 (fr)
JP (1) JP2011504110A (fr)
KR (1) KR101026502B1 (fr)
WO (1) WO2009066967A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511984A (ja) * 2009-11-25 2013-04-11 エリテック・ホールディング・ベスローテン・フェンノートシャップ 副溝結合剤（ＭＧＢ）−オリゴヌクレオチドｍｉＲＮＡアンタゴニスト
EP2395086A1 (fr) * 2010-06-09 2011-12-14 Chanel Parfums Beauté Inhibiteurs de micro-ARN pour une utilisation dans la prévention et/ou l'atténuation du vieillissement de la peau et/ou pour hydrater la peau
ES2459143T3 (es) * 2010-06-09 2014-05-08 Chanel Parfums Beauté Inhibidores de varios microARN para usar en la prevención y/o atenuación del envejecimiento cutáneo y/o para hidratar la piel
WO2012153854A1 (fr) * 2011-05-12 2012-11-15 学校法人立命館 Modulateur des cytokines-chimiokines
US9163235B2 (en) * 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
RU2718534C2 (ru) * 2015-06-05 2020-04-08 Мираджен Терапьютикс, Инк. Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl)
US20210254161A1 (en) * 2015-06-18 2021-08-19 Daegu Gyeongbuk Institute Of Science And Technology Method for determining decrease in functions of hippocampus by using correlation between micro rna and nmda receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions
JP6818889B2 (ja) * 2016-08-09 2021-01-20 シーサン・セラピューティクス 細胞透過性が向上したペプチド核酸複合体およびそれを含む薬学的組成物
KR20210107037A (ko) * 2018-12-21 2021-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 이식유전자 발현의 drg-특이적 감소를 위한 조성물
JP2022025558A (ja) * 2020-07-29 2022-02-10 学校法人帝京大学 ｍｉＲ－９６－５ｐインヒビターとそれを含有する医薬組成物
KR20240003760A (ko) * 2022-06-29 2024-01-09 서울대학교산학협력단 RNA 안정성 또는 mRNA 번역 증가용 신규 조절 엘리먼트,이와 상호작용하는 ZCCHC2, 및 이들의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071741A1 (en) * 2002-03-28 2007-03-29 Yongwon Choi OCL-2A3 compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
EP2386637B1 (fr) * 2001-09-28 2018-05-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molécules de micro arn
EP2530157B1 (fr) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Composés oligomères et compositions à utiliser dans la modulation de miARNs
BRPI0415496A (pt) * 2003-10-14 2006-12-26 Novartis Ag microdisposição de oligonucleotìdeo
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
EP2287303B1 (fr) * 2004-11-12 2014-07-02 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
CA2618995A1 (fr) * 2005-08-10 2007-02-22 The Rockefeller University Oligonucleotides chimiquement modifies pouvant etre employes dans la modulation de micro-arn et applications
WO2008015662A1 (fr) * 2006-08-04 2008-02-07 Dublin City University Procédé d'obtention de produits biologiques recombinants
US20080199961A1 (en) * 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
JP2010505427A (ja) * 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
JP5334565B2 (ja) * 2008-12-24 2013-11-06 矢崎総業株式会社 自動車用ルームランプの取付構造

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071741A1 (en) * 2002-03-28 2007-03-29 Yongwon Choi OCL-2A3 compositions and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of EP2215228A4 *
STAHLHUT ESPINOSA C.E. ET AL.: "The role of microRNAs in cancer.", YALE JOURNAL OF BIOLOGY AND MEDICINE., vol. 79, December 2006 (2006-12-01), pages 131 - 140, XP008136291 *
TURNER J.J. ET AL.: "RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA.", BLOOD CELLS, MOLECULES AND DISEASE., vol. 38, no. 1, 17 November 2006 (2006-11-17), pages 1 - 7, XP005733323 *
YI FAN ET AL.: "Detection of MicroRNAs Using Target-Guided Formation of Conducting Polymer Nanogaps", J. AM. CHEM. SOC., vol. 129, 6 April 2007 (2007-04-06), pages 5437 - 5443, XP008136292 *

Also Published As

Publication number Publication date
JP2011504110A (ja) 2011-02-03
KR101026502B1 (ko) 2011-04-01
US20100240058A1 (en) 2010-09-23
EP2520649A2 (fr) 2012-11-07
KR20090053743A (ko) 2009-05-27
WO2009066967A2 (fr) 2009-05-28
EP2215228A4 (fr) 2012-01-11
EP2520649A3 (fr) 2013-02-20
EP2215228A2 (fr) 2010-08-11

Similar Documents

Publication Publication Date Title
WO2009066967A3 (fr) Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer
WO2006020768A3 (fr) Oligonucleotides chimiquement modifies
AP2012006191A0 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same.
WO2007059007A3 (fr) Marqueurs d'endoderme definitif
WO2007027894A3 (fr) Composes antisens ayant une activite anti-microarn amelioree
WO2008066642A3 (fr) Systèmes d'administration par voie transdermique
IL211889A (en) Pyrazolo pyridine derivatives, preparations containing them and their use as nadph oxidase inhibitors
WO2007107789A3 (fr) Traitement des maladies du snc
WO2008152131A3 (fr) Inhibition par arni de l'expression du canal alpha-enac
IL181436A0 (en) Transdermal antiemesis delivery system, method and composition therefor
HK1224181A1 (zh) 抑制 氧化酶活性的組合物
WO2009085277A3 (fr) Traitement de cicatrices anormales ou excessives
WO2009003090A9 (fr) Compositions et procédés d'inhibition d'activité virale et bactérienne
WO2005118824A3 (fr) Methodes et compositions inhibant l'expression genique
WO2010033495A3 (fr) Agonistes de l'adrénorécepteur α2c à base d'azanitrile fonctionnellement sélectifs
WO2009042270A3 (fr) Inhibiteurs reca et leurs utilisations en tant qu'inhibiteurs microbiens ou potentiateurs d'une activité antibiotique
WO2007140205A3 (fr) Procédés de traitement de fibrose
HK1218658A1 (zh) 蛋白酶 抑制劑及其方法和組合物
IL197758A0 (en) Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof
IL179076A0 (en) Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
EP1864670A4 (fr) Inhibiteur de l activité de la sucrase, inhibiteur de l activité de la glucoamylase et aliment et nourriture contenant ceux-ci
GB2435262B (en) Method, composition and articles
WO2008021135A8 (fr) Composition synérétique, procédé et article associés
WO2007132355A3 (fr) Compositions et procédés pour inhiber l'adhésion virale
EP1959982A4 (fr) Procédés et compositions servant à prévenir et/ou traiter la pancréatite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08851799

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12741413

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008851799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010534896

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载